

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SANVO Fine Chemicals Group Limited

三和精化集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 301)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

The board (the **"Board"**) of directors (the **"Directors"**) of SANVO Fine Chemicals Group Limited (the **"Company"**, together with its subsidiaries, the **"Group"**) hereby announces that Mr. Jian Ziqing (**"Mr. Jian"**) has been appointed as an independent non-executive Director, a member of the audit committee of the Company, a member of the remuneration committee of the Company (the **"Remuneration Committee"**), a member of the nomination committee of the Company and a member of the environmental, social and governance committee of the Company with effect from 2 October 2026.

The biography of Mr. Jian is as follows:

Mr. Jian, aged 56, has extensive experience in medical technology and technology research and development. He obtained a bachelor's degree in Pharmacology from China Pharmaceutical University in Nanjing in 1988.

Mr. Jian served as a research and development staff member, assistant director and director of the research institute of Zhongshan Xiaolan Pharmaceutical Factory from September 1993 to December 1996, a research and development staff member, registration officer, product manager and senior sales manager of Sanofi Winthrop Pharmaceuticals Limited (France) from January 1997 to October 2008, the general manager of Zhongshan Zhida Hezhong Medical Devices Co., Ltd. from October 2008 to August 2015 and an executive director and the general manager of Zhongshan Jiahe Medical Technology Co., Ltd. from August 2015 to April 2026. He has been an executive director and the general manager of Zhongshan Rupu Medical Technology Co., Ltd. since April 2026.

The Company has entered into a letter of appointment with Mr. Jian for a term of three years, subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company and the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Mr. Jian is entitled to a remuneration of RMB240,000 per annum. His remuneration is determined by the Board with reference to his duties, capabilities and performance, the operating conditions of the Company, industry remuneration benchmarks and prevailing market conditions, upon the recommendation of the Remuneration Committee of the Company.

Mr. Jian has confirmed to the Company that: (a) he has met all of the independence criteria as set out in Rules 3.13(1) to (8) of the Listing Rules; (b) he does not have and has not had any financial or other interests in the business of the Company or its subsidiaries or any connections with any core connected persons (as defined in the Listing Rules) of the Company; and (c) there are no other factors that may affect his independence at the time of his appointment.

As at the date of this announcement and save as disclosed above, Mr. Jian (i) does not hold any other positions in the Company or any of its subsidiaries or any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years; (ii) does not hold any other major appointments and professional qualifications; (iii) does not have any relationship with any other Directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information or matter that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, nor is there any other matter relating to the appointment of Mr. Jian as an independent non-executive Director that needs to be brought to the attention of the shareholders of the Company.

The Board would like to extend its warm welcome to Mr. Jian for joining the Board.

By Order of the Board
SANVO Fine Chemicals Group Limited
Mr. Chen Bingqiang
*Chairman, Chief Executive Officer
and Executive Director*

Hong Kong, 2 October 2026

As at the date of this announcement, the executive Directors are Mr. Chen Bingqiang and Mr. Ng Cheuk Lun; the non-executive Director is Ms. Wang Xiaorong; and the independent non-executive Directors are Ir. Daniel Lai, Mr. Xu Kai, Mr. Yeung Chun Yue David and Mr. Jian Ziqing.